SCHEMBL2493587

SCHEMBL2493587

CCS(=O)(=O)N1CCN(c2cnc(N)c(-c3nnc(-c4cccs4)o3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATR Q13535 11/20 0.46
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 6/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 4/20 0.40
HPGD P15428 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
GBA1 P04062 1/20 0.39
HSD17B10 Q99714 3/20 0.39
TP53 P04637 2/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
GSK3B P49841 1/20 0.38
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615700 0.84 ATR (0.61) ATRGSK3BPRKDC
SCHEMBL2489781 0.84 ATR (0.43) ATRKDM4EALDH1A1MAPTGSK3B
SCHEMBL2492765 0.82 ATR (0.45) ATRKDM4EALDH1A1MAPTHSD17B10
SCHEMBL2491689 0.82 ATR (0.46) ATRKDM4EALDH1A1MAPTNPC1
SCHEMBL2529491 0.82 ATR (0.50) ATRKDM4EALDH1A1MAPTNPC1
SCHEMBL2497637 0.82 ATR (0.46) ATRKDM4EALDH1A1MAPTNPC1
SCHEMBL10255396 0.81 MEN1 (0.43) KDM4EALDH1A1MAPTNPC1HPGD
SCHEMBL2527297 0.80 ATR (0.52) ATRGSK3BPRKDC
SCHEMBL2527580 0.79 ATR (0.53) ATRGSK3BPRKDC
SCHEMBL618078 0.79 ATR (0.54) ATRKDM4EMAPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885KDM4E 2868/4885ALDH1A1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.